Search Results
Your search for The ASCO Post matches 17100 pages
Showing 551 - 600
Christian U. Blank, MD, PhD, on Melanoma: Potentially Practice-Changing Results From the NADINA Trial
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses findings of an investigator-initiated phase III trial showing that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival in patients with macroscopic, resectable...
Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial
Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in...
Jens Marquardt, MD, and Jens Hoeppner, MD, on Esophageal Cancer: Phase III Findings on Chemotherapy vs Chemoradiation
Jens Marquardt, MD, of the University of Lübeck, and Jens Hoeppner, MD, of the University of Bielefeld, discuss findings from the ESOPEC trial, which showed that perioperative chemotherapy (fluorouracii, leucovorin, oxaliplatin, docetaxel) and surgery improves survival in patients with resectable...
Lisa A. Carey, MD, and Kevin Kalinsky, MD, on Advanced Breast Cancer: New Data on Abemaciclib and Fulvestrant From the postMONARCH Trial
Lisa A. Carey, MD, of University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Kevin Kalinsky, MD, of the Winship Cancer Institute of Emory University, discuss the first phase III findings showing a benefit of continued CDK4/6 inhibition with abemaciclib plus...
Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data
Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).
Denise A. Yardley, MD, on Early Breast Cancer: Findings From the NATALEE Trial on Patients With Node-Negative Disease
Denise A. Yardley, MD, of the Sarah Cannon Research Institute, discusses the NATALEE trial, which assessed ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) vs an NSAI alone in patients with hormone receptor–positive/HER2-negative early breast cancer at increased risk of recurrence,...
Ana C. Garrido-Castro, MD, on Managing Metastatic Breast Cancer in 2024
Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, discusses recent approvals of multiple novel therapies for metastatic breast cancer, weighing their potential benefits and risks, understanding the mechanisms that drive response and resistance, and exploring how to optimally sequence them ...
Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab
Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).
Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Recruiting for the CELESTIAL-TNCLL Study
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses an ongoing phase III study of the BCL2 inhibitor sonrotoclax plus zanubrutinib vs venetoclax and obinutuzumab for patients with treatment-naive chronic lymphocytic leukemia. The investigators are recruiting internationally (see...
Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed...
Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel
Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent...
CAR T-Cell Therapy in Patients With Central Nervous System Lymphoma
A chimeric antigen receptor (CAR) T-cell therapy approved for patients with large B-cell lymphoma has produced positive results in a pilot study involving patients with relapsed, treatment-resistant central nervous system (CNS) lymphoma. These findings from a small cohort were presented by Nayak et ...
Antibody-Drug Conjugate Plus Checkpoint Inhibitor for PD-L1–Positive, HR-Positive/HER2-Negative Breast Cancer
In patients with metastatic hormone receptor (HR)-positive/HER2-negative breast cancer unselected by PD-L1 status, adding the immune checkpoint inhibitor pembrolizumab to the antibody-drug conjugate sacituzumab govitecan-hziy resulted in a 1.9-month improvement in median progression-free survival...
Shorter Durations of Venetoclax Yield Similar Response Rates Compared to Standard Course in AML
When combined with azacitidine, a 7-day course of venetoclax demonstrated similar remission rates and was more tolerable compared to the standard 28-day course for older or chemotherapy-ineligible patients with newly diagnosed acute myeloid leukemia (AML). These results from a retrospective...
Relapsed or Refractory B-Cell ALL: Novel CAR T-Cell Therapy Yields Strong Remission Rates
The novel anti-CD19 autologous chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) without a subsequent stem cell transplant, according to results from the phase...
American Cancer Society and ASCO Announce Expanded Patient-Centered Online Collaboration
The American Cancer Society (ACS) and ASCO today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership between ASCO, the leading organization for cancer care providers, and ACS, the leading patient education, support,...
Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07
Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).
Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent
Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of patients with advanced non–small cell lung cancer (Abstract 8601).
Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib
Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual...
Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial
Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as...
Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab
Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses the ongoing phase III BELLWAVE-010 study of nemtabrutinib plus venetoclax vs venetoclax plus rituximab in previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic...
FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma
On May 30, the U.S. Food and Drug Administration (FDA) approved the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy, including a...
Lorlatinib vs Crizotinib for Advanced ALK-Positive NSCLC: Extended CROWN Follow-up
The CROWN study (ClinicalTrials.gov identifier NCT03052608) of lorlatinib, a brain-penetrant, third-generation ALK tyrosine kinase inhibitor, vs crizotinib, an inhibitor of receptor tyrosine kinases (including ALK), in the first-line treatment of patients with advanced ALK-positive non–small cell...
Can a Novel Combination Therapy Improve Metastatic Colorectal Cancer Outcomes?
A novel combination comprising experimental immunotherapy drugs plus chemotherapy may improve survival outcomes in previously treated patients with metastatic colorectal cancer compared to the targeted therapy regorafenib alone. These findings will be presented by Wainberg et al at the 2024 ASCO...
Differences in Prostate Cancer Genomics Among U.S. Veterans
Researchers have uncovered differences in the genomic makeup of metastatic prostate cancer cells among U.S. veterans that may be associated with race and ethnicity. These findings will be presented by Valle et al at the 2024 ASCO Annual Meeting (Abstract 5017). The research could translate into...
Cyclophosphamide May Enable More Patients With High-Risk Hematologic Malignancies to Receive Stem Cell Transplants
A novel treatment strategy using cyclophosphamide-based graft-vs-host disease prophylaxis may enable more patients with high-risk hematologic malignancies to receive stem cell transplantation from mismatched unrelated donors. These findings were presented by Al Malki et al at the 2024 ASCO Annual...
For an International Expert in Gynecologic Cancer, Being Reared by Educators Who Stressed Knowledge and Service Was Key
Deputy Editor of The ASCO Post, Jame Abraham, MD, FACP, recently spoke with gynecologic cancer expert Sharmila K. Makhija, MD, MBA, about her journey to her current position as Founding Dean and Chief Executive Officer of the Alice L. Walton School of Medicine, Bentonville, Arkansas. Raised by...
Born in a Small Village in India, a Breast Cancer Expert Assumes a Leadership Role in Oncology in Cleveland and Beyond
Jame Abraham, MD, FACP, was born and reared in Kerala, a tropical state in southwestern India. Situated on the Malabar Coast, Kerala was named as one of the ten paradises of the world by National Geographic Traveler. “Along with its natural beauty, Kerala is a true melting pot. Over centuries,...
FDA’s Crowdsourcing Initiative to Benefit Patient-Centric Clinical Trial Innovation
The U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE) recently announced a new initiative called “Project 5 in 5.” Project 5 in 5 is a crowdsourcing initiative to ultimately identify five clinically relevant questions that can be answered through use of pragmatic...
Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past dozen years, many in the oncology community have been profiled in this special issue. A complete list of individuals...
FDA Grants Accelerated Approval to Selpercatinib for Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Other Solid Tumors
On May 29, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the RET inhibitor selpercatinib (Retevmo) for pediatric patients aged 2 years and older with the following: Advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved...
Are Tattoos Linked to a Heightened Risk of Lymphoma?
Tattoos may be a risk factor in the development of lymphoma, according to a recent study published by Nielsen et al in eClinicalMedicine. Background A majority of individuals receive their first tattoos at a young age, exposing them to tattoo ink for a larger portion of their lives. The long-term...
ASTRO Releases Updated Clinical Guidelines on Radiation Therapy for Patients With Bone Metastases
The American Society for Radiation Oncology (ASTRO) outlined recommendations on best practices for treating patients with symptomatic bone metastases and strategies to improve their quality of life, according to updated clinical guidelines published by Alcorn et al in Practical Radiation Oncology....
Pancreatic Cancer: Sociodemographic Disparities and Fragmented Care
Investigators found that fragmented care may be more prevalent among patients with pancreatic adenocarcinoma who receive single-modality neoadjuvant therapy compared with those who receive total neoadjuvant therapy, according to findings presented by Taylor et al during Digestive Disease Week (DDW) ...
Can Exercise Boost the Efficacy of Rituximab in Treatment of CLL?
Sessions of moderate-to-vigorous exercise may improve the efficacy of antibody therapies, such as rituximab, used to treat chronic lymphocytic leukemia (CLL), according to a recent study published by Collier-Bain et al in Brain, Behavior, and Immunity. The findings may demonstrate the potential of...
Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally
A ground breaking staging system for de novo metastatic breast cancer has been validated in an international cohort, perhaps paving the way for more personalized care and improved outcomes for patients diagnosed with this challenging disease. The staging system, developed by surgical oncologist...
Patient Characteristics May Impact Results of AI Algorithm–Interpreted Screening Mammograms
Investigators have found that patient characteristics such as age and race may influence false-positive results from artificial intelligence (AI)-interpreted screening mammograms, according to a recent study published by Nguyen et al in Radiology. Background Although preliminary data suggested that ...
Rosai-Dorfman Disease: Sinus Histiocytosis With Massive Lymphadenopathy
“Don’t be afraid to give up the good to go for the great.” — John D. Rockefeller The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the ...
NCCN Appoints Chair, Vice-Chair of Board of Directors
The National Comprehensive Cancer Network (NCCN®) has announced the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022. “The exemplary leadership from our Board...
The Future of Cancer Care
The profound progress in cancer care since President Richard Nixon signed the National Cancer Act of 1971 into law is evidenced by the soaring number of cancer survivors since the law went into effect. In the 1970s, there were 3 million cancer survivors1; today, there are more than 18 million, and...
A Look Back on an Impactful and Inspiring Presidential Year
Serving as ASCO’s 60th President over the past year has been an honor and a privilege, said Lynn M. Schuchter, MD, FASCO, who will end her Presidential term during ASCO’s Annual Meeting, being held from May 31 to June 4, 2024, in Chicago, and welcome incoming President Robin Zon, MD, FACP, FASCO,...
Applying the Power of Knowledge to Drive Positive Change in Oncology Care
An ASCO volunteer for nearly 30 years, Robin T. Zon, MD, FACP, FASCO, is humbled and honored to be elected ASCO’s 61st President, effective during the 2024 ASCO Annual Meeting, May 31 to June 4, 2024, in Chicago and online. Dr. Zon began her 4-year term in June 2023 as President-Elect and will...
Dance/Movement Therapy for Pediatric Oncology Patients and Their Caregivers
Guest Editor’s Note: Children with cancer and their caregivers face physical and psychosocial challenges during and after treatment. Dance/movement therapy has been used to improve well-being, promote healthy coping, and mitigate the impact of illness, but limited knowledge exists regarding its...
Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, Joins Perthera as Chief Medical Officer
Perthera, an industry leader in precision oncology decision support, recently announced that Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, joined Perthera as Chief Medical Officer. Dr. Raghavan is founding President of the Levine Cancer Institute and former Chair and Director of the Cleveland...
Apply Through July 31, 2024, for Survivorship Champion’s Prize
Children’s Cancer Cause, a national advocacy group in pioneering research and innovation for pediatric cancer, announced it is accepting applications for the Survivorship Champion’s Prize. This award is presented to a group, program, or institution that has demonstrated significant advancements in...
Study Explores How Partner Relationships Impact the Well-Being of Breast Cancer Survivors
Diagnosis and treatment of breast cancer place significant stress on survivors, their partners, and their relationships. A recent study from researchers at the Regenstrief Institute and Indiana University (IU)’s Schools of Nursing, Science, and Medicine is one of the first to examine the impact of...
Understanding the Legal and Ethical Challenges AI Poses in Oncology
The field of oncology is experiencing a revolution driven by artificial intelligence (AI) technology. Artificial intelligence tools are already being used in medical imaging analysis, treatment planning, and even patient counseling. These advancements hold immense promise for earlier cancer...
USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer
On April 30, 2024, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer.1 The USPSTF now recommends that all women undergo screening for breast cancer every other year starting at age 40 and continuing through age 74. More...
FDA Withdraws Approval of Cholangiocarcinoma Drug Indication for FGFR Inhibitor
On May 16, the U.S. Food and Drug Administration (FDA) announced the final withdrawal of the approval of infigratinib (Truseltiq) for previously treated patients with unresectable, locally advanced, or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other...
Survival Outcomes Following Adjuvant Therapy in Patients With Clinical T2N0 Rectal Adenocarcinoma
Adjuvant therapy may be underutilized in patients with clinical T2N0 rectal adenocarcinoma, according to new findings presented by Kripalani et al at Digestive Disease Week (DDW) 2024 (Abstract 439). Background Patients with clinical T2N0 rectal adenocarcinoma have disease that has spread past the...
